Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, 56126, Pisa, Italy.
Curr Oncol Rep. 2024 Apr;26(4):359-376. doi: 10.1007/s11912-024-01505-w. Epub 2024 Mar 7.
This review describes the most relevant studies found in the scientific literature regarding metronomic chemotherapy (MCT) in the geriatric oncology population to support its use as a feasible treatment of care in the frail elderly patients.
Recent years have seen a reevaluation of cancer chemotherapeutic drugs and MCT is an emerging schedule in phase II and III clinical trials. Ageing is one of the risk factors for the development of cancer, the incidence of whom increases dramatically in people who live longer. To date, standard oncological protocols involve chemotherapeutic drugs in short cycles of therapy at the maximum tolerated dose (MTD). Although these therapeutic regimens may be successful, they can cause important adverse drug reactions, especially in elderly or frail patients. MCT is a different modality of delivery of chemotherapeutic drugs (frequent low dose for prolonged time) and it looks at the overcoming of the limitations and disadvantages of MTD, in particular the toxicity aspect. We reviewed the experience of clinicians who have used MCT in clinical trials enrolling elderly patients with different cancer types.
本篇综述描述了老年肿瘤患者肿瘤治疗中节拍化疗（MCT）的相关研究，以支持其在体弱老年患者的治疗中作为可行的治疗方案。
近年来，癌症化疗药物重新受到评估，MCT 是正在进行的 II 期和 III 期临床试验的新兴方案。衰老本身就是癌症发生的一个危险因素，随着人类寿命的延长，癌症的发病率也急剧上升。迄今为止，标准肿瘤学方案包括在最大耐受剂量（MTD）下的短周期治疗中使用化疗药物。虽然这些治疗方案可能有效，但它们会引起严重的药物不良反应，尤其是在老年或体弱患者中。MCT 是一种不同的化疗药物给药方式（长时间频繁给予低剂量），旨在克服 MTD 的局限性和缺点，特别是毒性方面。我们综述了临床医生在临床试验中使用 MCT 治疗不同类型癌症老年患者的经验。
